ArticleJournal of neuroinflammation2021
Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well?
Article in Journal of neuroinflammation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- Memantine administration in patients with optic neuritis: a double blind randomized clinical trial.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Trial
- Clinical and Modifiable Factors Associated With Disability and Relapse in MOGAD: A Multicentre Cohort Study.Annals of clinical and translational neurology · 2026Article
- Functional and structural outcomes in paediatric myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a prospective study.Documenta ophthalmologica. Advances in ophthalmology · 2026Article
- A rare presentation of pediatric MOG-antibody-associated neuroretinitis: a case report.BMC neurology · 2026Article
- From the Optic Neuritis Treatment Trial to Antibody-Mediated Optic Neuritis: Four Decades of Progress and Unanswered Questions.Biomedicines · 2026Review
- Significant Visual Field Defects Persist Despite Excellent Visual Acuity Following Optic Neuritis in Myelin-Oligodendrocyte Glycoprotein Associated Disease.Neuro-ophthalmology (Aeolus Press) · 2026Article
- MOGAD: A Shifting Landscape-From Pathogenesis to Personalised Management, Global Perspectives and Latin American Insights.Biomedicines · 2025Review
- Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.Neurology · 2025Article
- [Optic neuritis-Patient sees nothing, doctor sees nothing? : A case of myelin oligodendrocyte glycoprotein antibody-associated optic neuritis].Die Ophthalmologie · 2025Article
- Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks.Journal of neurology, neurosurgery, and psychiatry · 2025Article
- Translational insights from EAE models : decoding MOGAD pathogenesis and therapeutic innovation.Frontiers in immunology · 2025Review
- Worse recovery from acute attacks and faster disability accumulation highlights the unmet need for improved treatment in patients with late-onset neuromyelitis optica spectrum disorders (COPTER-LO study).Frontiers in immunology · 2025Article
- Biomarkers for diagnosis and prognosis of myelin oligodendrocyte glycoprotein antibody-associated disease - review article.Frontiers in immunology · 2025Review
- Rapid differentiation of MOGAD and MS after a single optic neuritis.Journal of neurology · 2024Article
- Article
- Clinical spectrum of myelin oligodendrocyte glycoprotein antibody-associated disease in Brazil: a single-center experience.Arquivos de neuro-psiquiatria · 2023Article
- Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges.Journal of neurology · 2023Review
- Attack phenotypes and disease course in pediatric MOGAD.Annals of clinical and translational neurology · 2023Review
- Delimiting MOGAD as a disease entity using translational imaging.Frontiers in neurology · 2023Review
- Characteristic retinal atrophy pattern allows differentiation between pediatric MOGAD and MS after a single optic neuritis episode.Journal of neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 11 institutions in 5 countries.
Funding
Abstract
backgroundTo investigate age-related severity, patterns of retinal structural damage, and functional visual recovery in pediatric and adult cohorts of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) optic neuritis (ON).
methodsAll MOGAD patients from the 5 participating centers were included. Patients with initial manifestation <18 years were included in the pediatric (MOGAD
resultsTwenty MOGAD
conclusionPediatric MOGAD ON showed better visual recovery than adult MOGAD ON despite profound and almost identical neuroaxonal retinal atrophy. Age-related cortical neuroplasticity may account for the substantial discrepancy between structural changes and functional outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.